Trials / Completed
CompletedNCT00920439
Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Months – 24 Months
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PoliorixTM | Single dose, intramuscular administration. |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-08-03
- Completion
- 2009-08-03
- First posted
- 2009-06-15
- Last updated
- 2018-01-19
- Results posted
- 2017-10-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00920439. Inclusion in this directory is not an endorsement.